NovoCure (NVCR) Share-based Compensation (2014 - 2026)

NovoCure's Share-based Compensation history runs 13 years deep, the most recent figure standing at $63.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 113.21% year-over-year to $63.0 million; the TTM figure through Mar 2026 stood at $138.3 million (down 11.07% YoY), while the FY2025 annual figure was $104.8 million, down 34.49% from the prior year.
• Share-based Compensation came in at $63.0 million for Q1 2026 at NovoCure, up from $19.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $63.0 million in Q1 2026 to a low of $17.4 million in Q4 2023.
• A 5-year average of $32.4 million and a median of $29.6 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 259.89% in 2024 and plunged 68.42% in 2025, its largest moves.
• NovoCure's Share-based Compensation stood at $29.8 million in 2022, then slumped by 41.45% to $17.4 million in 2023, then surged by 259.89% to $62.8 million in 2024, then slumped by 68.42% to $19.8 million in 2025, then surged by 217.97% to $63.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $63.0 million, $19.8 million, and $29.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison